Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.
Crinetics falls after mid-stage trial data adrenal disorder therapy
Crinetics Pharmaceuticals (CRNX) stock fell after Phase 2 results for its experimental drug atumelnant for congenital adrenal hyperplasia. Read more here.
Science Daily20h
Harnessing microwave flow reaction to convert biomass into useful sugars
Researchers have developed a new process that uses microwave flow reaction and recyclable solid catalysts to efficiently hydrolyze polysaccharides into simple sugars. The developed device utilizes a ...
Hippocratic AI secures $141m in Series B funding
Healthcare-focused AI startup Hippocratic AI has closed its Series B financing round, raising $141m, led by venture capital ...
Investor's Business Daily on MSN23h
Stocks Generating Improved Relative Strength: Alnylam Pharmaceuticals
Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...
Investor's Business Daily on MSN23h
Alkermes Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
Rating on Friday, rising from 69 to 74. Please watch the video at Investors.com - How To Find Game-Changing Stocks This proprietary rating tracks technical performance by showing how a stock's price ...